ARTICLE | Clinical News
Avastin bevacizumab: Phase III start
July 21, 2008 7:00 AM UTC
This quarter, Genentech will begin the Phase III SWOG S0502 trial to evaluate once-daily Gleevec with or without 15 mg/kg Avastin bevacizumab given every 3 weeks in 572 patients. The company had orig...